Literature DB >> 56399

Generation of cytotoxic T lymphocytes in vitro. VII. Suppressive effect of irradiated MLC cells on CTL response.

F W Fitch, H D Engers, J C Cerottini, K T Bruner.   

Abstract

Irradiated cells obtained from MLC at the peak of the CTL response caused profound suppression of generation of CTL when added in small numbers at the initiation of primary MLC prepared with normal spleen cells. The inhibitory activity of the MLC cells was not affected by irradiation (1000 rads) but was abolished by treatment with anti-theta serum and complement. The suppression was immunologically specific. The response of A (H-2a) spleen cells toward C3H (H-2k) alloantigens was suppressed by irradiated MLC cells obtained from MLC prepared with A spleen cells and irradiated C3H-stimulating cells, whereas the response of A spleen cells toward DBA/2 (H-2d) alloantigens was affected relatively little. However, if irradiated C3H X DBA/2 F1 hybrid spleen cells were used to stimulate A spleen cells in MLC, addition of irradiated MLC cells having cytotoxic activity toward C3H antigens abolished the response to both C3H and DBA/2 antigens. The response to DBA/2 antigens was much less affected when a mixture of irradiated C3H and DBA/2 spleen cells was used as stimulating cells. Thus, the presence of MLC cells having cytotoxic activity toward one alloantigen abolished the response to another non-cross reacting antigen only when both antigens were present on the same F1 hybrid-stimulating cells. This suppression of generation of CTL by irradiated MLC cells apparently involves inactivation of alloantigen-bearing stimulating cells as a result of residual cytotoxic activity of the irradiated MLC cells. This mechanism may be active during the decline in CTL activity noted in the normal immune response in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56399

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Analysis of immunosuppression generated by the graft-versus-host reaction. II. Characterization of the suppression cell and its mechanism of action.

Authors:  F L Shand
Journal:  Immunology       Date:  1976-12       Impact factor: 7.397

Review 2.  Identification and characterization of CD8+ suppressor T cells.

Authors:  James C Zimring; Judith A Kapp
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  PPD-induced blastogenesis is auto-regulated by suppressor cells generated in vitro.

Authors:  N Aoki; L J Degroot
Journal:  Experientia       Date:  1979-11-15

4.  Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A.

Authors:  F Esquivel; C E Taylor; P J Baker
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

5.  Regulation of herpes simplex virus-specific lymphoproliferation by suppressor cells.

Authors:  D W Horohov; R N Moore; B T Rouse
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

Review 6.  T cell subsets participating in the generation of cytotoxic T cells.

Authors:  M M Simon; K Eichmann
Journal:  Springer Semin Immunopathol       Date:  1980-05

7.  The induction of suppressor cells in mixed leucocyte cultures and in mixed leucocyte-non-lymphoid cell cultures.

Authors:  G Pawelec
Journal:  Immunology       Date:  1980-01       Impact factor: 7.397

8.  Regulation of human cytotoxic lymphocyte responses. I. Non-cytolytic suppression mediated by alloantigen-activated cells.

Authors:  P S Crosier; B C Broom
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

9.  Regulation of human cytotoxic lymphocyte responses. II. Suppression by a soluble factor produced by primed lymphocytes.

Authors:  P S Crosier; B C Broom
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

10.  Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression.

Authors:  C D Mills; R J North; E S Dye
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.